Questioning Future Combinations and Targets for CAR T Cell in DLBCL
Lori A. Leslie, MD, discusses chimeric antigen receptor T-cell therapy as a treatment for diffuse large B-cell lymphoma and the positive results demonstrated for this agent in patients with relapsed/refractory disease.
Lori A. Leslie, MD, a lymphoma oncologist at the John Theurer Cancer Center at Hackensack University Medical Center, discusses chimeric antigen receptor (CAR) T-cell therapy as a treatment for diffuse large B-cell lymphoma (DLBCL) and the positive results demonstrated for this agent in patients with relapsed/refractory disease.
This is an exciting space, Leslie says. CAR T-cell therapies have shown long-term remissions of about 40%. Leslie is particularly interested in the mechanisms of resistance because even though CAR T-cell therapies are effective, she wants to know why certain patients are progressing or having a lack of response. This may be because of the loss of CD19 or different CD19 epitopes, Leslie suggests.
Further development of CAR T-cell therapy will bring up other questions, such as what other therapies can be combined with it and how we can create different targets for CAR T-cell therapy in order to increase efficacy and produce more long-term complete responses, according to Leslie.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
